EVAX:NASDAQEvaxion A/S Analysis

Evaxion A/S shows encouraging clinical momentum, highlighted by Phase II data that demonstrated a high proportion of vaccine targets eliciting immune responses and an expanded AI‑Immunology platform now reaching glioblastoma indications. Technically, the stock sits near a key support level with RSI hovering around the neutral zone and a MACD that has turned bearish, while beta is well above one and volatility remains markedly high, suggesting pronounced price swings.
Fundamentally, the company is still operating at a loss with negative margins, no revenue growth, and a PE multiple that dwarfs the industry average, rendering the current valuation stretched despite analyst targets that imply substantial upside. The balance sheet is cash‑rich and debt‑free, providing runway, but the lack of cash flow and high drawdown risk underscore the speculative nature of the investment.